Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes.

dc.contributor.authorFarias, Virgínea de Araújo
dc.contributor.authorTovar, Isabel
dc.contributor.authorDel Moral, Rosario
dc.contributor.authorO'Valle, Francisco
dc.contributor.authorExpósito, José
dc.contributor.authorOliver, Francisco Javier
dc.contributor.authorRuiz de Almodóvar, José Mariano
dc.date.accessioned2025-01-07T14:07:54Z
dc.date.available2025-01-07T14:07:54Z
dc.date.issued2020-01-08
dc.description.abstractIn this paper, we summarize published articles and experiences related to the attempt to improve radiotherapy outcomes and, thus, to personalize the radiation treatment according to the individual characteristics of each patient. The evolution of ideas and the study of successively published data have led us to envisage new biophysical models for the interpretation of tumor and healthy normal tissue response to radiation. In the development of the model, we have shown that when mesenchymal stem cells (MSCs) and radiotherapy are administered simultaneously in experimental radiotherapy on xenotumors implanted in a murine model, the results of the treatment show the existence of a synergic mechanism that is able to enhance the local and systemic actions of the radiation both on the treated tumor and on its possible metastasis. We are convinced that, due to the physical hallmarks that characterize the neoplastic tissues, the physical-chemical tropism of MSCs, and the widespread functions of macromolecules, proteins, and exosomes released from activated MSCs, the combination of radiotherapy plus MSCs used intratumorally has the effect of counteracting the pro-tumorigenic and pro-metastatic signals that contribute to the growth, spread, and resistance of the tumor cells. Therefore, we have concluded that MSCs are appropriate for therapeutic use in a clinical trial for rectal cancer combined with radiotherapy, which we are going to start in the near future.
dc.identifier.doi10.3389/fonc.2019.01381
dc.identifier.issn2234-943X
dc.identifier.pmcPMC6960107
dc.identifier.pmid31970082
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6960107/pdf
dc.identifier.unpaywallURLhttps://www.frontiersin.org/articles/10.3389/fonc.2019.01381/pdf
dc.identifier.urihttps://hdl.handle.net/10668/26163
dc.journal.titleFrontiers in oncology
dc.journal.titleabbreviationFront Oncol
dc.language.isoen
dc.organizationSAS - Hospital Universitario San Cecilio
dc.organizationSAS - Hospital Universitario Virgen de las Nieves
dc.organizationInstituto de Investigación Biosanitaria de Granada (ibs.GRANADA)
dc.page.number1381
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectabscopal effect
dc.subjectbystander effect
dc.subjectcell loss
dc.subjectexosomes
dc.subjectexperimental radiotherapy
dc.subjectmesenchymal cell enhancement ratio
dc.subjectmesenchymal cells
dc.titleEnhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number9

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC6960107.pdf
Size:
647.51 KB
Format:
Adobe Portable Document Format